A new antiviral agent (P2) in the purpose of treatment of bovine leukemia.
Thirty five cows and heifers, all positive reactors on ID test and all showing persistent lymphocytosis (15 with markedly enlarged lymphatic glands) were divided in 4 experimental groups and treated with P-2, a new antiviral agent, previously shown to be effective for several RNA type viruses. In table are indicated groups, range of dosages of P-2, and variability in WBC and lymphocyte. White blood cells found to be at the lowest level (P less than 0.02) one month after treatment with P-2, a less marked reduction (P less than 0.05) was found when the experiments ended at 7 months. A significant (P less than 0.05) fall in lymphocytes was found one month after treatment but this was not significant at the end of experiment. In 12 animals with lymphosarcomatous disease significant retraction of lymphatic glands. It is not clear whether the sudden drop in WBC and lymphocytes is due to the virostatic effect of drug or an effect of drug per se. New series of experiments will be made to treat BLV with two agents: one virostatic and other cytostatic.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D002417:Cattle; D002418:Cattle Diseases / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005557:Formaldehyde / Q000031:analogs & derivatives / Q000627:therapeutic use; D007938:Leukemia / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D001909:Leukemia Virus, Bovine; D011108:Polymers / Q000627:therapeutic use*
D000998:Antiviral Agents; D011108:Polymers; D005557:Formaldehyde; D001205:Ascorbic Acid